Enrollment failure signals
Enrollment failure in clinical trials is not the same as drug failure
Enrollment failure is one of the most common reasons trials stop, but it should not be confused with biological failure. It often says more about feasibility than whether a drug works.
- The current database contains 7,173 stopped records with enrollment, recruitment, or accrual-related language.
- 5,470 of those records are terminated, 1,584 are withdrawn, and 119 are suspended.
- Oncology is the largest disease area in this enrollment-related slice with 2,583 records.
- Enrollment failure can reflect feasibility, trial design, competition, site activation, patient availability, or changing standards of care.
- These records are useful, but they should not be read as automatic proof that an intervention failed biologically.
The short version
Enrollment failure is a real clinical development problem, but it is not the same thing as a failed drug. A trial can stop because it cannot recruit enough patients, even if the intervention was never properly tested.
That distinction is important. If you mix enrollment stops with efficacy or safety failures, you can make the wrong conclusion about a sponsor, disease area, target, or drug class.
What enrollment failure can mean
Enrollment-related stop language can include slow accrual, poor recruitment, insufficient accrual, unable to enroll, or sites not recruiting as planned. Those phrases often point to feasibility and execution problems rather than a biological signal.
Sometimes that feasibility problem is still highly informative. It can show that a patient population is too narrow, the trial burden is too high, the competitive landscape changed, or the protocol did not fit clinical reality.
Why oncology shows up so often
Oncology is the largest disease area in the enrollment-related slice. That makes sense: cancer studies can involve biomarker restrictions, competing trials, fast-moving standards of care, narrow eligibility, and complex treatment pathways.
An oncology enrollment stop should therefore be read carefully. It may tell you something about study feasibility, not necessarily whether the therapy could work.
How I would analyze it
I would group enrollment stops by disease area, phase, sponsor, and condition, then look for repeats. One enrollment stop is a single operational story. Repeated enrollment stops in the same niche may be a real development warning.
The useful question is not simply did the trial fail. The better question is what failed: biology, safety, recruitment, trial design, or sponsor execution?
Enrollment-related stopped records
| Dataset signal | Current records |
|---|---|
| Enrollment, recruitment, or accrual signals | 7,173 |
| Terminated | 5,470 |
| Withdrawn | 1,584 |
| Suspended | 119 |
Largest disease areas
| Disease area | Records |
|---|---|
| Oncology | 2,583 |
| Other | 1,692 |
| Gastroenterology & Hepatology | 480 |
| Infectious Disease | 479 |
| Cardiovascular | 441 |
| Neurology | 265 |
Largest sponsor counts
| Sponsor | Records |
|---|---|
| M.D. Anderson Cancer Center | 148 |
| National Cancer Institute (NCI) | 141 |
| Mayo Clinic | 82 |
| Massachusetts General Hospital | 71 |
| Northwestern University | 61 |
| Wake Forest University Health Sciences | 59 |
Continue from here
FAQ
Is enrollment failure a clinical trial failure?
Yes, it can be a trial execution failure, but it is not automatically a biological or drug failure.
Why do trials fail to enroll?
Common reasons include narrow eligibility, competing trials, patient availability, site activation problems, trial burden, changed standard of care, or sponsor execution issues.
How should I compare enrollment stops?
Compare them by disease area, phase, sponsor, condition, and repeated patterns, then verify the source NCT records before drawing conclusions.
Source note: counts are generated from the current ClinicalTrials.gov-derived stopped-trial dataset used by ClinicalTrialFailures.com. These labels are analytical screening signals, not medical advice.